Baird Maintains Outperform on Medpace Hldgs, Lowers Price Target to $430
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Eric Coldwell maintains an Outperform rating on Medpace Holdings (NASDAQ:MEDP) but lowers the price target from $469 to $430.

July 24, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Eric Coldwell maintains an Outperform rating on Medpace Holdings but lowers the price target from $469 to $430.
The Outperform rating suggests continued confidence in Medpace Holdings' performance, but the lowered price target indicates a more conservative outlook on its short-term valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100